K. Aoki

发表

Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management

K. Aoki, 2003, Headache.

The structure and mode of action of different botulinum toxins

J. Dolly, K. Aoki, 2006, European journal of neurology.

Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

J. Dolly, F. Meunier, J. Molgó, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Botulinum Toxin A in Anal Fissure: Why Does It Work?

W. Jost, K. Aoki, 2004, Diseases of the colon and rectum.

Novel chimeras of botulinum and tetanus neurotoxins yield insights into their distinct sites of neuroparalysis

L. Wheeler, J. Dolly, G. Lawrence, 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.

M. Oshima, M. Atassi, K. Aoki, 2012, Immunobiology.

Mapping of the Antibody and T Cell Recognition Profiles of the HN Domain (Residues 449–859) of the Heavy Chain of Botulinum Neurotoxin A in Two High-Responder Mouse Strains

M. Atassi, K. Aoki, B. Z. Dolimbek, 2005, Immunological investigations.

Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A.

M. Atassi, K. Aoki, P. Deitiker, 2005, Molecular immunology.

Pharmacology of botulinum neurotoxins

K. Aoki, 2004 .

Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2008, Molecular immunology.

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

K. Aoki, J. Rubino, Minglei Cui, 2004, Pain.

Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

K. Aoki, 2005, Neurotoxicology.

A Highly Specific Monoclonal Antibody for Botulinum Neurotoxin Type A-Cleaved SNAP25

K. Aoki, E. Fernández-Salas, Brian B. Cai, 2015, Toxins.

Two Protein Trafficking Processes at Motor Nerve Endings Unveiled by Botulinum Neurotoxin E

J. Dolly, G. Lawrence, Jiafu Wang, 2007, Journal of Pharmacology and Experimental Therapeutics.

Botulinum neurotoxin — from laboratory to bedside

H. Bigalke, K. Aoki, K. Foster, 2006, Neurotoxicity Research.

Pharmacology and Immunology of Botulinum Neurotoxins

K. Aoki, 2005, International ophthalmology clinics.

Mode of action of botulinum neurotoxins: current vaccination strategies and molecular immune recognition.

Leonard A. Smith, M. Atassi, K. Aoki, 2010, Critical reviews in immunology.

Botulinum toxin for the treatment of dystonia

K. Aoki, J. M. Leon, M. Grayston, 1994 .

Future aspects of botulinum neurotoxins

K. Aoki, 2007, Journal of Neural Transmission.

Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution.

J. Dolly, K. Aoki, L. F. Chasseaud, 2003, Toxicon : official journal of the International Society on Toxinology.

Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.

K. Aoki, 2002 .

Is the light chain subcellular localization an important factor in botulinum toxin duration of action?

Helen Ho, K. Aoki, E. Fernández-Salas, 2004, Movement disorders : official journal of the Movement Disorder Society.

Preclinical update on BOTOX® (botulinum toxin type A)‐purified neurotoxin complex relative to other botulinurn neurotoxin preparations

K. Aoki, 1999 .

Inhibition of Botulinum Neurotoxin A Toxic Action In Vivo by Synthetic Synaptosome- and Blocking Antibody-Binding Regions

M. Atassi, K. Aoki, B. Z. Dolimbek, 2010, The protein journal.

Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies

M. Atassi, K. Aoki, T. Maruta, 2006, Journal of Neuroscience Methods.

Synaptotagmin II and Gangliosides Bind Independently with Botulinum Neurotoxin B but Each Restrains the Other

M. Atassi, K. Aoki, Midori Taruishi, 2014, The Protein Journal.

Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.

M. Bodeker, J. Dolly, J. Meng, 2012, The Biochemical journal.

Location of the synaptosome-binding regions on botulinum neurotoxin B.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2012, Biochemistry.

Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.

J. Jankovic, M. Atassi, K. Aoki, 2012, Immunobiology.

Chapter 5 – Immune Recognition of Botulinum Neurotoxins A and B: Molecular Elucidation of Immune Protection Against the Toxins

M. Atassi, K. Aoki, 2009 .

The binding sites on botulinum neurotoxin B for synaptotagmin and for blocking antibodies.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2008, Biochemical and biophysical research communications.

Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.

J. Jankovic, M. Atassi, K. Aoki, 2008, Molecular immunology.

Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission.

S. Ovsepian, J. Dolly, G. Lawrence, 2012, The Biochemical journal.

Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies.

J. Jankovic, M. Atassi, K. Aoki, 2011, Immunobiology.

Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2011, Immunobiology.

Drug Insight: biological effects of botulinum toxin A in the lower urinary tract

W. C. Groat, C. Fowler, M. Chancellor, 2008, Nature Clinical Practice Urology.

A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.

K. Aoki, K.R Aoki, 2001, Toxicon : official journal of the International Society on Toxinology.

Mapping of the Synaptosome-Binding Regions on the Heavy Chain of Botulinum Neurotoxin A By Synthetic Overlapping Peptides Encompassing the Entire Chain

M. Atassi, K. Aoki, T. Maruta, 2004, The protein journal.

Understanding the Role of Botulinum Toxin A in the Treatment of the Overactive Bladder—More than Just Muscle Relaxation

A. Apostolidis, K. Aoki, A. Haferkamp, 2006 .

Antibodies against a synthetic peptide designed to mimic a surface area of the H chain of botulinum neurotoxin A.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2012, Immunology letters.

Physiology and pharmacology of therapeutic botulinum neurotoxins.

K. Aoki, 2002, Current problems in dermatology.

Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain.

Wei-Jen Lin, K. Aoki, Li Zhang, 2003, Gene.

Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients.

J. Jankovic, M. Oshima, M. Atassi, 2016, Immunobiology.

Botulinum toxin: a successful therapeutic protein.

K. Aoki, 2004, Current medicinal chemistry.

Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A

Leonard A. Smith, J. Dolly, G. Lawrence, 2003, The Journal of Biological Chemistry.

Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions

K. Aoki, K R Aoki, B Guyer, 2001, European journal of neurology.

Pharmacology and immunology of botulinum toxin serotypes

K. Aoki, 2001, Journal of Neurology.

Excitatory Cholinergic and Purinergic Signaling in Bladder Are Equally Susceptible to Botulinum Neurotoxin A Consistent with Co-Release of Transmitters from Efferent Fibers

J. Dolly, G. Lawrence, K. Aoki, 2010, Journal of Pharmacology and Experimental Therapeutics.

Therapeutic effectiveness of botulinum neurotoxin A: Potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25

S. Ovsepian, J. Dolly, G. Lawrence, 2013, Neuropharmacology.

Pharmacology and immunology of botulinum toxin type A.

K. Aoki, K.Roger Aoki, 2003, Clinics in dermatology.

Plasma membrane localization signals in the light chain of botulinum neurotoxin.

Helen Ho, K. Aoki, E. Fernández-Salas, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Updates on the antinociceptive mechanism hypothesis of botulinum toxin A.

K. Aoki, J. Francis, 2011, Parkinsonism & related disorders.

Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential

S. Ovsepian, J. Dolly, M. Pickering, 2009, The Journal of Neuroscience.

Human T-cell responses to botulinum neurotoxin Proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients

J. Jankovic, M. Oshima, M. Atassi, 2011, Journal of Neuroimmunology.

Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.

J. Jankovic, M. Atassi, K. Aoki, 2007, Molecular immunology.

Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

M. Brin, R. Burstein, K. Aoki, 2014, Cephalalgia : an international journal of headache.

Identification of Fibroblast Growth Factor Receptor 3 (FGFR3) as a Protein Receptor for Botulinum Neurotoxin Serotype A (BoNT/A)

R. Stevens, J. Dupuy, K. Aoki, 2013, PLoS pathogens.

Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules

M. Oshima, M. Atassi, H. Graham, 2017, Journal of Neuroimmunology.

Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans

J. Jankovic, M. Oshima, M. Atassi, 2011, Autoimmunity.

Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay

K. Aoki, E. Fernández-Salas, Ester Fernández-Salas, 2012, PloS one.

The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.

K. Aoki, R. Broide, J. Rubino, 2013, Toxicon : official journal of the International Society on Toxinology.

Using translational medicine to understand clinical differences between botulinum toxin formulations

J. Wissel, D. Ranoux, K. Aoki, 2006, European journal of neurology.

The C-Terminal Heavy-Chain Domain of Botulinum Neurotoxin A Is Not the Only Site That Binds Neurons, as the N-Terminal Heavy-Chain Domain Also Plays a Very Active Role in Toxin-Cell Binding and Interactions

M. Atassi, B. V. Ayyar, K. Aoki, 2015, Infection and Immunity.

Novel Chimeras of Botulinum Neurotoxins A and E Unveil Contributions from the Binding, Translocation, and Protease Domains to Their Functional Characteristics*

M. Bodeker, J. Dolly, G. Lawrence, 2008, Journal of Biological Chemistry.

Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.

G. Molenaers, J. Wissel, I. Autti-Rämö, 2000, Gait & posture.

Characterization of Förster resonance energy transfer in a botulinum neurotoxin protease assay.

Dudley H. Williams, D. Jameson, J. A. Ross, 2011, Analytical biochemistry.

Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury

G. Somogyi, Christopher P. Smith, K. Aoki, 2008, Neurochemistry International.

BOTULINUM TOXIN TYPE A NORMALIZES ALTERATIONS IN UROTHELIAL ATP AND NO RELEASE CAUSED BY CHRONIC SPINAL CORD INJURY

G. Somogyi, Christopher P. Smith, K. Aoki, 2008 .

Regions recognized on the light chain of botulinum neurotoxin type A by T lymphocytes of SJL and BALB/c mice primed with inactivated toxin.

M. Oshima, M. Atassi, K. Aoki, 2014, Immunobiology.

Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates

M. Atassi, K. Aoki, B. Z. Dolimbek, 2014, Journal of Neuroimmunology.

Reduction of antibody response against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol-peptide conjugates.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2011, Immunology letters.

Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B

J. Jankovic, M. Oshima, M. Atassi, 2011, Journal of Neuroimmunology.

Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.

M. Atassi, K. Aoki, B. Z. Dolimbek, 2007, Critical reviews in immunology.

Fusion of Golgi‐derived vesicles mediated by SNAP‐25 is essential for sympathetic neuron outgrowth but relatively insensitive to botulinum neurotoxins in vitro

M. Brin, L. Wheeler, J. Dolly, 2014, The FEBS journal.

A peptide‐based immunoassay for antibodies against botulinum neurotoxin A

J. Jankovic, K. Aoki, P. Deitiker, 2007, Journal of molecular recognition : JMR.